BTIG Downgrades Aardvark Therapeutics to Neutral

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc.

AARD

0.00

BTIG analyst Jeet Mukherjee downgrades Aardvark Therapeutics (NASDAQ: AARD) from Buy to Neutral.